143 related articles for article (PubMed ID: 36523718)
1. Larotrectinib in NTRK Fusion-Positive High-Grade Glioneuronal Tumor: A Case Report.
Tadipatri R; Eschbacher J; Fonkem E; Kresl J; Azadi A
Cureus; 2022 Nov; 14(11):e31449. PubMed ID: 36523718
[TBL] [Abstract][Full Text] [Related]
2. Glioneuronal tumor with ATRX alteration, kinase fusion and anaplastic features (GTAKA): a molecularly distinct brain tumor type with recurrent NTRK gene fusions.
Bogumil H; Sill M; Schrimpf D; Ismer B; Blume C; Rahmanzade R; Hinz F; Cherkezov A; Banan R; Friedel D; Reuss DE; Selt F; Ecker J; Milde T; Pajtler KW; Schittenhelm J; Hench J; Frank S; Boldt HB; Kristensen BW; Scheie D; Melchior LC; Olesen V; Sehested A; Boué DR; Abdullaev Z; Satgunaseelan L; Kurth I; Seidlitz A; White CL; Ng HK; Shi ZF; Haberler C; Deckert M; Timmer M; Goldbrunner R; Tauziède-Espariat A; Varlet P; Brandner S; Alexandrescu S; Snuderl M; Aldape K; Korshunov A; Witt O; Herold-Mende C; Unterberg A; Wick W; Pfister SM; von Deimling A; Jones DTW; Sahm F; Sievers P
Acta Neuropathol; 2023 May; 145(5):667-680. PubMed ID: 36933012
[TBL] [Abstract][Full Text] [Related]
3. Clinical and radiographic response following targeting of BCAN-NTRK1 fusion in glioneuronal tumor.
Alvarez-Breckenridge C; Miller JJ; Nayyar N; Gill CM; Kaneb A; D'Andrea M; Le LP; Lee J; Cheng J; Zheng Z; Butler WE; Multani P; Chow Maneval E; Ha Paek S; Toyota BD; Dias-Santagata D; Santagata S; Romero J; Shaw AT; Farago AF; Yip S; Cahill DP; Batchelor TT; Iafrate AJ; Brastianos PK
NPJ Precis Oncol; 2017; 1(1):5. PubMed ID: 29872694
[TBL] [Abstract][Full Text] [Related]
4. High-grade glioneuronal tumor with an ARHGEF2-NTRK1 fusion gene.
Kurozumi K; Nakano Y; Ishida J; Tanaka T; Doi M; Hirato J; Yoshida A; Washio K; Shimada A; Kohno T; Ichimura K; Yanai H; Date I
Brain Tumor Pathol; 2019 Jul; 36(3):121-128. PubMed ID: 31011918
[TBL] [Abstract][Full Text] [Related]
5. Primary Resistance to Larotrectinib in a Patient With Squamous NSCLC With Subclonal
Boulanger MC; Temel JS; Mino-Kenudson M; Ritterhouse LL; Dagogo-Jack I
JTO Clin Res Rep; 2023 Apr; 4(4):100501. PubMed ID: 37095749
[TBL] [Abstract][Full Text] [Related]
6. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
[TBL] [Abstract][Full Text] [Related]
7. A novel NCOR2-NTRK1 fusion detected in a patient of lung adenocarcinoma and response to larotrectinib: a case report.
Zhang L; Liu H; Tian Y; Wang H; Yang X
BMC Pulm Med; 2021 Apr; 21(1):125. PubMed ID: 33865348
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Pediatric Soft Tissue Sarcoma with LMNA-NTRK1 Gene Fusion Treated with Larotrectinib under Single Patient Expanded Access System].
Kato S; Fujimura J; Nozaki Y; Yamaguchi S; Takagi T; Hayashi T; Saito T; Henry D; Ku N; Suehara Y
Gan To Kagaku Ryoho; 2019 Oct; 46(10):1595-1597. PubMed ID: 31631147
[TBL] [Abstract][Full Text] [Related]
9. Antitumor Activity of Larotrectinib in Esophageal Carcinoma with NTRK Gene Amplification.
Hempel D; Wieland T; Solfrank B; Grossmann V; Steinhard J; Frick A; Hempel L; Eberl T; Gaumann A
Oncologist; 2020 Jun; 25(6):e881-e886. PubMed ID: 32323889
[TBL] [Abstract][Full Text] [Related]
10. A Unique Case Report of Infant-Type Hemispheric Glioma (Gliosarcoma Subtype) with TPR-NTRK1 Fusion Treated with Larotrectinib.
Mançano BM; Dos Reis MB; Moreno DA; de Paula FE; de Almeida Junior CR; Cavalcante CEB; Zanon MF; Santana IVV; Matsushita MM; Reis RM
Pathobiology; 2022; 89(3):178-185. PubMed ID: 35034013
[TBL] [Abstract][Full Text] [Related]
11. A rapid and durable response to larotrectinib in a patient with
Ando Y; Morita S; Shimokata T; Tsuzuki T; Inafuku S; Iwami K; Brega N; Akagawa T; Tsujino T; Ogawa T
Int Cancer Conf J; 2022 Oct; 11(4):242-246. PubMed ID: 36186229
[TBL] [Abstract][Full Text] [Related]
12. Clinical, pathologic, and genomic characteristics of two pediatric glioneuronal tumors with a CLIP2::MET fusion.
Chapman N; Greenwald J; Suddock J; Xu D; Markowitz A; Humphrey M; Cotter JA; Krieger MD; Hawes D; Ji J
Acta Neuropathol Commun; 2024 Apr; 12(1):63. PubMed ID: 38650040
[TBL] [Abstract][Full Text] [Related]
13. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.
DuBois SG; Laetsch TW; Federman N; Turpin BK; Albert CM; Nagasubramanian R; Anderson ME; Davis JL; Qamoos HE; Reynolds ME; Cruickshank S; Cox MC; Hawkins DS; Mascarenhas L; Pappo AS
Cancer; 2018 Nov; 124(21):4241-4247. PubMed ID: 30204247
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.
Carter-Febres M; Schneller N; Fair D; Solomon D; Perry A; Roy A; Linscott L; Alashari M; Kestle JR; Bruggers CS
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e987-e990. PubMed ID: 33093355
[TBL] [Abstract][Full Text] [Related]
15. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib.
Awada A; Berghmans T; Clement PM; Cuppens K; De Wilde B; Machiels JP; Pauwels P; Peeters M; Rottey S; Van Cutsem E
Crit Rev Oncol Hematol; 2022 Jan; 169():103564. PubMed ID: 34861380
[TBL] [Abstract][Full Text] [Related]
16. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome.
Zhao X; Kotch C; Fox E; Surrey LF; Wertheim GB; Baloch ZW; Lin F; Pillai V; Luo M; Kreiger PA; Pogoriler JE; Linn RL; Russo PA; Santi M; Resnick AC; Storm PB; Hunger SP; Bauer AJ; Li MM
JCO Precis Oncol; 2021; 1():. PubMed ID: 34036219
[TBL] [Abstract][Full Text] [Related]
17. Rare variant of large pediatric glioneuronal tumor with novel MYO5A::NTRK3 fusion: illustrative case.
Chenoweth D; Syed H; Teferi N; Challa M; Persons JE; Eschbacher KL; Seblani M; Dlouhy BJ
J Neurosurg Case Lessons; 2024 Mar; 7(10):. PubMed ID: 38437672
[TBL] [Abstract][Full Text] [Related]
18. Anaplastic glioneuronal tumor with
Liu L; Narayan P; Xiong J; Xiong Z
Intractable Rare Dis Res; 2019 Nov; 8(4):279-282. PubMed ID: 31890457
[TBL] [Abstract][Full Text] [Related]
19. Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors.
Konicek BW; Capen AR; Credille KM; Ebert PJ; Falcon BL; Heady GL; Patel BKR; Peek VL; Stephens JR; Stewart JA; Stout SL; Timm DE; Um SL; Willard MD; Wulur IH; Zeng Y; Wang Y; Walgren RA; Betty Yan SC
Oncotarget; 2018 Mar; 9(17):13796-13806. PubMed ID: 29568395
[TBL] [Abstract][Full Text] [Related]
20. Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion.
Filippi R; Depetris I; Satolli MA
Expert Opin Pharmacother; 2021 Apr; 22(6):677-684. PubMed ID: 33576301
[No Abstract] [Full Text] [Related]
[Next] [New Search]
